ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "IVIG"

  • 2015 American Transplant Congress

    Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab

    A. Vo, J. Choi, I. Kim, J. Kahwaji, A. Peng, R. Villicana, S. Jordan.

    Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…
  • 2015 American Transplant Congress

    Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection

    A. Vo, J. Choi, J. Kahwaji, D. Puliyanda, A. Peng, R. Villicana, S. Jordan.

    Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced antibody-mediated rejection (ABMR) and rebound B-cell activity. Recently,…
  • 2015 American Transplant Congress

    De Novo Donor Specific Antibody (DSA) After Treatment of BK Infection With Intravenous Immunoglobulin (IVIG)

    J. Kahwaji, P. Wongsaroj, J. Choi, A. Peng, R. Villicana, S. Jordan, A. Vo.

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: The primary treatment for polyomavirus BK viral infection (BKV) is a reduction in immunosuppression exposure. However this can lead to rejection and development of…
  • 2015 American Transplant Congress

    Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?

    M. Ravindranath, P. Terasaki, C. Maehara, V. Jucaud.

    HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.

    Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences